ABIVAX launches IPO on the regulated market of Euronext in Paris

  • Share capital increase of €43.6 million, that can reach a maximum of €57.7 million after exercise of the Extension Clause and of the Overallotment Option
  • Subscription undertakings representing €33 million
  • Indicative price range: €18.26 - €24.34 per share
  • Placement period: from June 5 to June 22
  • Eligible for French PEA PME investment regime

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41